Using Financial Incentives to Treat Stimulant Use Disorders
A Contingency Management Approach
Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH)
A multi-institutional Center of Excellence, funded by the National Institute on Drug Abuse.
The Center for Health Economics of Treatment Interventions for Substance Use Disorder, HCV, and HIV (CHERISH) is a multi-institutional Center of Excellence, funded by the National Institute on Drug Abuse. CHERISH is a collaborative effort among Penn LDI/University of Pennsylvania, Weill Cornell Medicine, Boston Medical Center, Boston University School of Public Health, and University of Miami Miller School of Medicine.
The mission of CHERISH is to develop and disseminate health economic research on healthcare utilization, health outcomes, and health-related behaviors that informs substance use disorder treatment policy and HCV and HIV care of people who use substances. To increase the impact of this research, CHERISH supports research conducted at the individual, system, and community levels.
The dissemination and policy core of CHERISH is led by Perelman School of Medicine faculty members and Penn LDI Fellows Zachary Meisel, Associate Professor of Emergency Medicine and Director of the Center for Emergency Care Policy Research and Margaret Lowenstein, Assistant Professor of Medicine.
CHERISH Dissemination and Policy Core
Zachary Meisel, MD, MPH
Director, Center for Emergency Care Policy Research; Associate Professor, Emergency Medicine, Perelman School of Medicine
Margaret Lowenstein, MD, MSHP
Assistant Professor, Medicine, Perelman School of Medicine
Featured Briefs
Lowering the Barriers to Medication Treatment for People with Opioid Use Disorder
Evidence for a Low-Threshold Approach
Expanding Access to Naloxone: A Review of Distribution Strategies
An LDI/CHERISH Issue Brief
Cost-Effective Screening and Treatment of Hepatitis C
The Case for Universal, One-Time Screening
National Variation in Opioid Prescribing and Risk of Prolonged Use for Opioid-Naive Patients Treated in the Emergency Department for Ankle Sprains
One in Four Patients Prescribed Opioids for Ankle Sprain Between 2011-2015
Featured Blog Posts
7 Ways to Improve an Already Effective Treatment for Stimulant Use Disorder
New Commentary Suggests Ways to Make Contingency Management More Effective For Drugs Like Cocaine and Methamphetamine
Chart of the Day: Rise in Patients with Opioid Use Disorder Leaving Hospital Prematurely
Untreated Withdrawal May Be the Cause, Researchers Say
Surgeons Are Closer to Predicting Which Patients Need Post-Surgery Opioids—and Which Ones Don’t
Prescribing by Pain Level, Age, and Previous Use May Reduce Excess Pills
Many State Medicaid Programs Still Require Prior Authorization for Buprenorphine Treatment for Opioid Use Disorder
Removing Barriers Could Improve Patient Outcomes
LDI Experts Analyze the New U.S. Plan to Target Xylazine-Laced Fentanyl
Some Doubt That It Goes Far Enough
New Federal Rules That Lower Barriers to Opioid Care Could Save Thousands of Lives
More Needs to Be Done to Stem the Opioid Epidemic, Say LDI Experts
A Catch-Up on Promising Efforts to Mitigate the Opioid Crisis
Q&A with Margaret (Maggie) Lowenstein
Paying Patients Can Improve Engagement in Mental Health Treatment
Research Supports Expanding the Practice Beyond Substance Use Disorder Treatment
Red Flags and Red Tape Hinder Access to Treatment for Opioid Use Disorder
Pharmacy Barriers to Buprenorphine in the United States
Providing Naloxone in the Emergency Department Can Save Lives
At-Risk Patients who Received Education Plus Naloxone in the Emergency Department Reported Increased Likelihood of Carrying it
Overcoming Barriers to Treatment for Opioid Use Disorder
Research Shows That Emergency Departments Can Be a Gateway to MOUDs
Prescription Drug Monitoring Program Mandates Affect Use of Opioids to Treat Acute, Severe Pain
Potential Unintended Consequences for Patients with Sickle Cell Disease and Boney Cancer Pain
Distributing Naloxone by Mail in Philadelphia During the COVID-19 Pandemic
Reducing Harm, Saving Lives
Buprenorphine for Opioid Use Disorder Lowers Overdose Risk in Commercially Insured Individuals
Real-world effectiveness shown
Selling Naloxone Over the Counter Likely to Boost Sales
CHERISH investigators model out-of-pocket price and demand